2024-09-21 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis

### Company Overview

Eli Lilly and Co. is a global pharmaceutical company specializing in the development and manufacturing of a wide range of medications, including diabetes, oncology, and neuroscience treatments.

### Performance Analysis

**1. Performance vs. S&P 500**

LLY has significantly outperformed the S&P 500 (VOO) with an **875.98% cumulative return** compared to VOO's **133.16%**. This results in a **742.82%** difference, placing LLY at **92.18%** on the relative divergence scale. This indicates LLY has performed significantly better than the broader market over the historical period.

**2. Recent Price Movement**

* Closing Price: **906.03**
* 5-Day Moving Average: **913.06**
* 20-Day Moving Average: **930.51**
* 60-Day Moving Average: **898.08**

This indicates a recent downward trend, with the stock trading below both the 5-day and 20-day moving averages. However, the 60-day moving average suggests potential support for the stock price.

**3. Technical Indicators**

* RSI: **38.99** - This suggests the stock is currently oversold, indicating potential for a rebound.
* PPO: **-0.6** - This indicates a bearish momentum, with the price falling behind its moving average.
* Delta_Previous_Relative_Divergence: **-7.62** - This suggests a recent decline in relative performance, indicating a potential short-term downward trend.
* Expected_Return: **63.18%** - This suggests a potential for high returns over the next 5-10 years, making it potentially attractive for long-term investors.

**4. Recent Earnings & Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings (2024-08-08) showed **EPS of 3.29**, exceeding analyst expectations. Revenue reached **11.30 B$**, indicating strong growth. This positive performance suggests a positive outlook for LLY.

### Conclusion

Overall, LLY shows a strong track record of outperformance compared to the market, with strong fundamentals and a recent positive earnings report. The stock is currently oversold, but with potential for rebound based on its long-term growth potential. While the short-term trend might be bearish, the long-term outlook for LLY remains positive, making it a potentially attractive investment opportunity for long-term investors.  However, investors should consider their individual risk tolerance and conduct further research before making any investment decisions. 
